126 related articles for article (PubMed ID: 37070248)
1. Clinical characteristics of nasolacrimal duct obstruction after iodine therapy in differentiated thyroid cancer patients.
Li N; Zhang W
Ear Nose Throat J; 2023 Apr; ():1455613231170088. PubMed ID: 37070248
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.
Lee IT; Chen W; Chen Q; Cole HA; Bischoff LA; Jessop AC; Sobel RK
Endocr Pract; 2022 Dec; 28(12):1210-1215. PubMed ID: 35970353
[TBL] [Abstract][Full Text] [Related]
3. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases.
Al-Qahtani KH; Al Asiri M; Tunio MA; Aljohani NJ; Bayoumi Y; Munir I; AlAyoubi A
Clin Ophthalmol; 2014; 8():2479-84. PubMed ID: 25525325
[TBL] [Abstract][Full Text] [Related]
4. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer.
Fard-Esfahani A; Farzanefar S; Fallahi B; Beiki D; Saghari M; Emami-Ardekani A; Majdi M; Eftekhari M
Nucl Med Commun; 2012 Oct; 33(10):1077-80. PubMed ID: 22825036
[TBL] [Abstract][Full Text] [Related]
5. Probing for congenital nasolacrimal duct obstruction.
Petris C; Liu D
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011109. PubMed ID: 28700811
[TBL] [Abstract][Full Text] [Related]
6. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
7. Office probing for treatment of nasolacrimal duct obstruction in infants.
Miller AM; Chandler DL; Repka MX; Hoover DL; Lee KA; Melia M; Rychwalski PJ; Silbert DI; ; Beck RW; Crouch ER; Donahue S; Holmes JM; Quinn GE; Sala NA; Schloff S; Wallace DK; Foster NC; Frick KD; Golden RP; Lambert SR; Tien DR; Weakley DR
J AAPOS; 2014 Feb; 18(1):26-30. PubMed ID: 24568978
[TBL] [Abstract][Full Text] [Related]
8. Resolution of congenital nasolacrimal duct obstruction with nonsurgical management.
Pediatric Eye Disease Investigator Group
Arch Ophthalmol; 2012 Jun; 130(6):730-4. PubMed ID: 22801833
[TBL] [Abstract][Full Text] [Related]
9. A simple and evolutional approach proven to recanalise the nasolacrimal duct obstruction.
Chen D; Ge J; Wang L; Gao Q; Ma P; Li N; Li DQ; Wang Z
Br J Ophthalmol; 2009 Nov; 93(11):1438-43. PubMed ID: 19416937
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Endoscopic Dacryocystorhinostomy in Secondary Acquired Nasolacrimal Duct Obstruction: A Case-Control Study.
Sweeney AR; Davis GE; Chang SH; Amadi AJ
Ophthalmic Plast Reconstr Surg; 2018; 34(1):20-25. PubMed ID: 27997463
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Basal Serum Thyroglobulin Levels, but Not Basal Antithyroglobulin Antibody (TgAb) Levels, in Patients with Differentiated Thyroid Cancer.
Neshandar Asli I; Siahkali AS; Shafie B; Javadi H; Assadi M
Mol Imaging Radionucl Ther; 2014 Jun; 23(2):54-9. PubMed ID: 24963446
[TBL] [Abstract][Full Text] [Related]
12. Anisometropia and amblyopia in nasolacrimal duct obstruction.
Kipp MA; Kipp MA; Struthers W
J AAPOS; 2013 Jun; 17(3):235-8. PubMed ID: 23602456
[TBL] [Abstract][Full Text] [Related]
13. Lacrimal sac dacryoliths: predictive factors and clinical characteristics.
Yazici B; Hammad AM; Meyer DR
Ophthalmology; 2001 Jul; 108(7):1308-12. PubMed ID: 11425692
[TBL] [Abstract][Full Text] [Related]
14. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
15. The Microbiome of the Nasolacrimal System and Its Role in Nasolacrimal Duct Obstruction.
Curragh DS; Bassiouni A; Macias-Valle L; Vreugde S; Wormald PJ; Selva D; Psaltis AJ
Ophthalmic Plast Reconstr Surg; 2020; 36(1):80-85. PubMed ID: 31809480
[TBL] [Abstract][Full Text] [Related]
16. Tear protein analysis in patients with primary acquired nasolacrimal duct obstruction treated with lacrimal passage intubation.
Yaginuma S; Konno K; Shigeyasu C; Yamada M
Jpn J Ophthalmol; 2021 May; 65(3):409-415. PubMed ID: 33411097
[TBL] [Abstract][Full Text] [Related]
17. Symptom score questionnaire for nasolacrimal duct obstruction in adults--a novel tool to assess the outcome after endoscopic dacryocystorhinostomy.
Smirnov G; Tuomilehto H; Kokki H; Kemppainen T; Kiviniemi V; Nuutinen J; Kaarniranta K; Seppa J
Rhinology; 2010 Dec; 48(4):446-51. PubMed ID: 21442083
[TBL] [Abstract][Full Text] [Related]
18. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
Lee JY; Woo KI
Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
[No Abstract] [Full Text] [Related]
19. Antimetabolites as an adjunct to dacryocystorhinostomy for nasolacrimal duct obstruction.
Phelps PO; Abariga SA; Cowling BJ; Selva D; Marcet MM
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012309. PubMed ID: 32259290
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Microbial Keratitis and Nasolacrimal Duct Obstruction: Concordance, Etiopathogenesis, and Outcome.
Nayak A; Mitra Basu S; De A; Mallick A; Das S; Rath S
Cornea; 2019 Jan; 38(1):84-88. PubMed ID: 30325843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
